Abstract
Footnotes Competing interests None declared. Footnotes Competing interests None declared. Footnotes Competing interests None declared. References 1.↵ UKPDS Study Group . Effect of Intensive blood glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 43). Lancet 1998; 352: 854–865 2.↵ Lalau JD, Vermesh A, Hary L, Andrajek M, Isnard F, Quichaud J . Type 2 diabetes in the elderly: an assessment of metformin use in type 2 diabetes. Int Clin Pharmacol Ther Toxicol 1990; 28: 329–332 3.↵ Scottish Intercollegiate Guidelines Network . SIGN 55: Management of diabetes. A national clinical guideline. Edinburgh: Scottish Intercollegiate Guidelines Network, Royal College of Physicians, 2001. 4.↵ National Institute for Clinical Excellence . Management of type 2 diabetes—renal disease, prevention and early management. London: NICE, 2002. http://www.nice.org.uk/article.asp?a=27964 (accessed 21 Mar 2003). 5.↵ Deray G, Bellin MF, Boulchfar H, Baumelou B, Koskas F, Baumelou A, et al . Nephrotoxicity of contrast media in high risk patients with renal insufficiency: comparison of low- and high-osmolar contrast agents. Am J Nephrol 1991; 11: 309–312